Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07317505 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

A Phase 1 study of Cancer and Cancer (Solid Tumors), sponsored by Conjupro Biotherapeutics.

Recruiting
Registry status
Phase 1
Development phase
270
Enrollment target
3
Study locations

NCT07317505 is a Phase 1 study of Cancer and Cancer (Solid Tumors) that is actively recruiting participants, run by Conjupro Biotherapeutics. The registered enrollment target is 270 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07317505, a Phase 1 study of Cancer and Cancer (Solid Tumors), is actively recruiting participants, sponsored by Conjupro Biotherapeutics.

RECRUITING
Registry status
Phase 1
Development phase
270 participants
Enrollment target
3
Study locations

Study Summary

The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a) * To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b) * To evaluate how quickly JMT108 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To explore the pharmacodynamic (PD) characteristics of JMT108 * To explore the correlation between biomarker levels and preliminary efficacy Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive JMT108 by intravenous injection every 2 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years

Conditions Studied

Cancer Cancer (Solid Tumors)

Interventions

  • DRUG JMT108

Study Locations (3)

North Carolina

  • Carolina BioOncology Institute - Huntersville

Texas

  • NEXT Dallas - Dallas

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2025-12-02
Est. Completion 2029-09
Phase Phase 1

Sponsor

Conjupro Biotherapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07317505

The ClinicalTrials.gov registry entry for NCT07317505 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Conjupro Biotherapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which JMT108 is the first listed.

NCT07317505 reports 3 study locations spanning 3 distinct geographic areas - top geographies include North Carolina, Texas, Virginia.

Frequently Asked Questions

What is clinical trial NCT07317505 about?

NCT07317505 is a clinical study titled "A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors". The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of JMT108 at increasing doses and determine the dose ...

What is the current status of trial NCT07317505?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 270 participants. The study started on 2025-12-02. Estimated completion is 2029-09.

What conditions does trial NCT07317505 study?

This clinical trial studies the following conditions: Cancer, Cancer (Solid Tumors).

What interventions are being tested in trial NCT07317505?

The interventions under investigation include: JMT108 (DRUG).

Who is sponsoring clinical trial NCT07317505?

This trial is sponsored by Conjupro Biotherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07317505 being conducted?

This trial has 3 study locations across North Carolina, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Cancer (Solid Tumors)

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.